2359695-48-8
Chemical Structure
Deferoxamine-DBCO
Synonym(s): DFO-DBCO
- CAS No.: 2359695-48-8
- Formula:C44H61N7O10
- Molecular Weight:848.00
InChIKey: LFESCIZZXSUBAV-UHFFFAOYSA-N
SMILES: CC(N(CCCCCNC(CCC(N(CCCCCNC(CCC(N(CCCCCNC(CCC(N1CC2=C(C=CC=C2)C#CC3=C1C=CC=C3)=O)=O)O)=O)=O)O)=O)=O)O)=O
Biological Activity: Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as 89Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonal antibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Deferoxamine-DBCO | 89.08% | Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as 89Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonal antibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Sales ZS, et al. Practical syntheses of DOTAGA-DBCO and DFO-DBCO, strained alkyne pre-cursors to radioimmunoconjugates for targeted alpha therapy. Bioorg Med Chem. 2022 Nov 1;73:117010. [Content Brief]
- [2]. Hofstraat SRJ, et al. Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors. Nat Nanotechnol. 2025 Apr;20(4):532-542. [Content Brief]
- [3]. Huang F Y J, et al. Preparation and Characterization of Site-Specifically Radiolabeled 89Zr-DFO-anti-PD-L1-mAb ImmunoPET Tracer[J]. 2023.
Keywords
